6th Letter to the shareholders

Discover OPM’s 6th Letter to Shareholders!

Focus on

• $6.9 million in funding from the Michael J. Fox Foundation to accelerate the development of an innovative treatment for Parkinson’s disease
• The collaborative program launched by OPM and Ksilink to accelerate the discovery of new central nervous system therapies
• The granting of a patent for its new macrocyclic LRRK2 kinase inhibitors
• OPM wins the HealthTech Innovation Award